TABLE 4.
Multivariable analysis of levocarnitine supplementation and EOI MRD ≥0.01%
| Covariable | OR | 95% CI | p‐value a |
|---|---|---|---|
| Age, years | |||
| <15 years | Reference | ||
| ≥15 years | 1.12 | 0.49–2.54 | 0.534 |
| BMI Category b | |||
| Not obese | Reference | ||
| Obese | 1.67 | 0.74–3.77 | 0.215 |
| Presenting WBC | |||
| <50 K/uL | Reference | ||
| ≥50 K/uL | 3.32 | 1.42–7.72 | 0.005 |
| FISH/Cytogenetics c | |||
| Neutral | Reference | ||
| Favorable | 0.41 | 0.05–3.68 | 0.424 |
| Adverse | 2.40 | 0.98–5.89 | 0.056 |
| Unknown | 1.32 | 0.36–4.82 | 0.677 |
| Levocarnitine suppl. a | 1.68 | 0.62–4.58 | 0.309 |
Abbreviations: BMI, body mass index; FISH, Fluorescence in situ hybridization; WBC, white blood cell count.
a
Multivariable logistic regression model constructed from prognostic factors and levocarnitine supplementation then tested against model, see methods.
b
Obesity defined according to population norms for BMI in patients <20 years old (BMI percentile <95% vs. ≥95% and BMI <30 vs. ≥30 in patients ≥20 years old).
c
Classified as per Children's Oncology Group biology protocol AALL08B1 (modified to include Ph‐like signatures as adverse prognostic markers).